12:00 AM
 | 
Dec 09, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

PBT2: Phase II ongoing

Prana said a DSMB recommended continuation of the double-blind, placebo-controlled, Australian Phase II IMAGINE trial evaluating 250 mg oral PBT2 once daily for 1 year after completing its fifth and final safety review. The company...

Read the full 154 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >